Phase III SUGAR Study: (SBRT and Ultrashort GnRH Antagonist‐Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate cancer
Favorable intermediate risk (FIR) prostate cancers are typically treated with radiation therapy alone. However, cases that are classified as FIR by clinical appearance can act more aggressively if also associated with a high-risk gene expression score. These combined clinicogenomic risk factors present a treatment dilemma. Recent evidence suggests that androgen deprivation therapy (ADT) may benefit these patients but can also cause severe side effects. A new ADT drug, Relugolix, can reduce the amount of time patients take ADT which may reduce side effects. This benefit can be compounded by combining this with a shorter, more intense version of radiotherapy called stereotactic body radiation therapy (SBRT). Therefore, we will perform a multicenter randomized phase III study comparing prostate cancer control and quality of life with SBRT + Ultrashort GnRH Antagonist Relugolix (SUGAR) against SBRT alone for this category of prostate cancer patients. This will inform future patient classification and treatment strategies.
